This retrospective study included 84 individuals with acute PHN. The participants were divided into 3 groups. Group H was treated with interferon-α2b combined with high-voltage long-term PRF. Group C was treated with a combination of high-voltage, long-term PRF and a paravertebral injection (without recombinant human interferon-α2b), and group I was treated with interferon-α2b only. All the patients in the 3 groups were orally administered a 5-mg morphine hydrochloride quick-release tablet when a burst of pain occurred during treatment. The numerical rating scale for pain score, the interleukin-6 and galectin-3 levels, and the incidence of PHN were documented before and after therapy.
The pain intensity of all individuals decreased after therapy. Compared with group C, the numerical rating scale scores for group H were significantly reduced at 4, 8, and 12 weeks following therapy, and the PHN incidence was significantly lower. Compared with prior treatment, the recommended dosage of gabapentin capsules and immediate-release morphine hydrochloride tablets was reduced for group H. Compared with group C, the requirement for orally administrated gabapentin capsules and morphine hydrochloride tablets in group H was reduced significantly after treatment. No serious adverse reactions occurred in any of the 3 groups.
Within the context of treatment of acute PHN, the injection of interferon-α2b in conjunction with high-voltage, long-term application of PRF is more effective than PRF or the injection of interferon-α2b alone.
方法:这项回顾性研究是对84例急性PHN患者进行的。参与者分为三组。H组:干扰素-α2b联合高电压长期PRF治疗;C组:高电压长期PRF治疗;I组:干扰素-α2b治疗。3组患者均在治疗过程中出现阵阵疼痛时口服盐酸吗啡速释片5mg。疼痛数字评分(NRS),在治疗之前和之后记录IL-6、Gal-3和PHN的发生率。
结果:治疗后所有个体的疼痛强度均降低。与C组比较,H组NRS评分在治疗后4、8和12周时显著降低,PHN发生率明显较低。与之前的治疗相比,H组减少了加巴喷丁胶囊和盐酸吗啡速释片的推荐剂量。与C组相比,H组口服加巴喷丁胶囊和盐酸吗啡治疗后明显减少。三组患者均未出现严重不良反应。
结论:在治疗急性PHN的背景下,干扰素-α2b的注射结合高电压,PRF的长期应用比PRF或单独注射干扰素-α2b更有效。